Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus‐infected patients with renal impairment

• Published in: Hepatology research Vol. 47; no. 11; pp. 1127 - 1136
• Main Authors: Suda, Goki, Nagasaka, Atsushi, Yamamoto, Yoshiya, Furuya, Ken, Kumagai, Kenichi, Kudo, Mineo, Terashita, Katsumi, Kobayashi, Tomoe, Tsunematsu, Izumi, Yoshida, Junichi, Meguro, Takashi, Kimura, Megumi, Ito, Jun, Umemura, Machiko, Izumi, Takaaki, Tsunematsu, Seiji, Sato, Fumiyuki, Tsukuda, Yoko, Nakai, Masato, Sho, Takuya, Natsuizaka, Mitsuteru, Morikawa, Kenichi, Ogawa, Koji, Sakamoto, Naoya
• Format: Journal Article
• Language: English
• Published: Netherlands Wiley Subscription Services, Inc 01.10.2017
• Subjects: Alanine; Alanine transaminase; Anemia; Antiviral agents; asunaprevir; daclatasvir; direct‐acting antiviral; End-stage renal disease; Epidermal growth factor receptors; Glomerular filtration rate; Graft rejection; Grafts; Hemodialysis; Hepatitis; Hepatitis C; hepatitis C virus; Kidney diseases; Kidney transplantation; Renal failure; Renal function; Ribonucleic acid; RNA; hepatitis C virus; direct-acting antiviral; asunaprevir; daclatasvir

Aim Hepatitis C virus (HCV) infection is a risk factor for end‐stage renal disease, renal graft failure, and hemodialysis patient mortality. However, the efficacy of direct‐acting antiviral therapy for HCV‐infected patients with renal impairment is unclear. Additionally, the promising NS5B inhibitor...